Please use this identifier to cite or link to this item:
Scopus Web of Science® Altmetric
Full metadata record
DC FieldValueLanguage
dc.contributor.authorCaughey, G.-
dc.contributor.authorPreiss, A.-
dc.contributor.authorVitry, A.-
dc.contributor.authorGilbert, A.-
dc.contributor.authorRyan, P.-
dc.contributor.authorShakib, S.-
dc.contributor.authorEsterman, A.-
dc.contributor.authorMcDermott, R.-
dc.contributor.authorRoughead, E.-
dc.identifier.citationPharmacoepidemiology and Drug Safety, 2013; 22(6):615-622-
dc.description.abstract<h4>Purpose</h4>This study aimed to examine the effect of antidepressant use on persistence with newly initiated oral antidiabetic medicines in older people.<h4>Methods</h4>A retrospective study of administrative claims data from the Australian Government Department of Veterans' Affairs, from 1 July 2000 to 30 June 2008 of new users of oral antidiabetic medicines (metformin or sulfonylurea). Antidepressant medicine use was determined in the 6 months preceding the index date of the first dispensing of an oral antidiabetic medicine. The outcome was time to discontinuation of diabetes therapy in those with antidepressant use compared with those without. Competing risks regression analyses were conducted with adjustment for covariates.<h4>Results</h4>A total of 29,710 new users of metformin or sulfonylurea were identified, with 7171 (24.2%) dispensed an antidepressant. Median duration of oral antidiabetic medicines was 1.81 years (95% CI 1.72–1.94) for those who received an antidepressant at the time of diabetes medicine initiation, by comparison to 3.23 years (95% CI 3.10–3.40) for those who did not receive an antidepressant. Competing risk analyses showed a 42% increased likelihood of discontinuation of diabetes medications in persons who received an antidepressant (subdistribution hazard ratio 1.42, 95% CI 1.37–1.47, p < 0.001).<h4>Conclusions</h4>The results of this large population-based study demonstrate that depression may be contributing to non-compliance with medicines for diabetes and highlight the need to provide additional services to support appropriate medicine use in those initiating diabetes medicines with co-morbid depression.-
dc.description.statementofresponsibilityGillian E. Caughey, Adrian K. Preiss, Agnes I. Vitry, Andrew L. Gilbert, Philip Ryan, Sepehr Shakib, Adrian Esterman, Robyn A. McDermott and Elizabeth E. Roughead-
dc.publisherJohn Wiley & Sons Ltd-
dc.rightsCopyright © 2013 John Wiley & Sons, Ltd.-
dc.subjectSulfonylurea Compounds-
dc.subjectAntidepressive Agents-
dc.subjectHypoglycemic Agents-
dc.subjectRetrospective Studies-
dc.subjectCohort Studies-
dc.subjectAged, 80 and over-
dc.subjectInsurance Claim Review-
dc.subjectDrug Utilization Review-
dc.subjectMedication Adherence-
dc.titleDoes antidepressant medication use affect persistence with diabetes medicines?-
dc.typeJournal article-
dc.identifier.orcidCaughey, G. [0000-0003-1192-4121]-
dc.identifier.orcidShakib, S. [0000-0002-7199-5733]-
dc.identifier.orcidEsterman, A. [0000-0001-7324-9171]-
Appears in Collections:Aurora harvest
Public Health publications

Files in This Item:
There are no files associated with this item.

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.